Hormone Insight
by FWA
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·8 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 15 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes
Jun 28, 2026
1m 33s
Jun 27, 2026: This Week in Diabetes & Endocrinology -- The triple agonist arrives, and the bar moves
Jun 27, 2026
11m 58s
An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology
Jun 20, 2026
9m 32s
The Week in Endocrinology Oral Ozempic & Emerging Therapies
May 12, 2026
5m 01s
Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial
May 5, 2026
15m 56s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/28/26 | weight lossobesity+3 | — | semaglutideNew England Journal of Medicine | — | semaglutideSTEP 1 trial+3 | — | 1m 33s | ||
| 6/27/26 | diabetesendocrinology+4 | — | retatrutideCagriSema+7 | — | diabetesretatrutide+6 | — | 11m 58s | ||
| 6/20/26 | oral GLP-1type 2 diabetes+5 | — | orforglipronACP+2 | — | diabetesendocrinology+7 | — | 9m 32s | ||
| 5/12/26 | Oral Ozempicsemaglutide+4 | — | Oral Ozempicsemaglutide+2 | Canada | Oral Ozempicsemaglutide+5 | — | 5m 01s | ||
| 5/5/26 | diabetes updatesendocrinology+5 | — | Tandem Control-IQ Plustirzepatide+5 | CKD | diabetesendocrinology+7 | — | 15m 56s | ||
| 4/24/26 | DiabetesEndocrinology+4 | — | Tzield (Teplizumab)Orforglipron+7 | — | TzieldTeplizumab+6 | — | 13m 32s | ||
| 4/22/26 | DiabetesEndocrinology+4 | — | EnlicitideSemaglutide+3 | — | diabetesendocrinology+6 | — | 17m 41s | ||
| 4/9/26 | diabetesendocrinology+4 | — | Hormone InsightFWA+6 | — | LDL Under 55Medicare GLP-1+5 | — | 16m 45s | ||
| 4/5/26 | DiabetesEndocrinology+4 | — | OrforglipronSemaglutide+4 | — | DiabetesEndocrinology+5 | — | 23m 36s | ||
| 6/14/25 | Type 2 DiabetesTirzepatide+3 | — | TirzepatideDiabetes Care | — | Type 2 DiabetesTirzepatide+3 | — | 1m 14s | ||
| 1/4/25 | semaglutideobesity+3 | — | semaglutideNew England Journal of Medicine | 2024 | semaglutideobesity+3 | — | 0m 51s | ||
| 12/19/24 | diabetes treatmentsemaglutide+4 | — | semaglutidecanagliflozin+2 | Type 2 Diabetes | semaglutidecanagliflozin+4 | — | 1m 04s | ||
| 11/22/24 | heart failuretirzepatide+4 | — | tirzepatideNew England Journal of Medicine | obesity | tirzepatideheart failure+5 | — | 3m 38s | ||
| 11/18/24 | blood pressure controltype 2 diabetes+3 | — | New England Journal of Medicine | — | intensive blood-pressure controltype 2 diabetes+4 | — | 3m 36s | ||
| 10/20/24 | semaglutidetype 2 diabetes+5 | — | semaglutideGLP-1 analog+3 | — | semaglutidetype 2 diabetes+5 | — | 3m 39s |
Showing 15 of 15
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.